

**Table 3. Changes in clinical parameters in type 2 diabetic patients treated with empagliflozin or control (standard treatment).**

	<u>Empagliflozin</u>			<u>Control</u>			<i>Difference b/w groups</i>	
	baseline	Week 12	P value	baseline	Week 12	P values	<i>P values</i>	
N	31	31	–	18	18	–		
Body weight (Kg)	70.6±19.1	68.7±18.6	<0.0001	73.7±18.3	69.7±13.6	0.5074	0.0002	
BMI (kg/m <sup>2</sup> )	27.2±5.7	26.6±5.4	<0.0001	28.4±6.6	27.0±5.9	0.5653	0.0023	
Waist circumference (cm)	97.6±12.7	92.0±12.2	<0.0001	100.9±11.5	99.1±12.0	0.9807	<0.0001	
VFA (cm <sup>2</sup> )	106.0±49.9	96.3±47.2	0.0005	115.3±52.3	109.3±45.6	0.7047	0.1157	
SBP (mmHg)	134.5±19.5	129.6±21.2	0.0786	142.0±22.1	144.0±21.2	0.6735	0.1485	
DBP (mmHg)	76.9±12.0	76.4±12.8	0.9175	75.7±11.4	73.8±10.1	0.6391	0.6638	
FPG (mg/dl)	173.0±49.4	131.6±30.5	<0.0001	146.3±33.8	161.6±51.8	0.2638	0.0007	
HbA1c (%)	8.0±0.9	7.2±0.6	0.0005	7.6±0.6	7.8±0.9	0.3190	0.0016	
LDL-C (mg/dl)	93.3±24.5	96.9±27.4	0.1743	100.6±28.2	101.5±21.4	0.8970	0.6620	
Triglyceride (mg/dl)	104.5 (74.5, 144.5)	98.0 (63.0, 148.8)	0.2492	103.0 (69.5, 144.5)	95.5 (70.3, 162.3)	0.8904	0.4609	
HDL-C (mg/dl)	54.4±16.3	58.8±19.6	0.0006	52.4±15.0	54.6±15.9	0.3622	0.1381	
RLP-C (mg/dl)	5.1 (3.0, 7.9)	3.9 (2.8, 9.1)	0.2666	4.4 (2.6, 7.4)	3.9 (2.4, 10.5)	0.7354	0.2507	

AST (U/L)	22.5 (17.0, 30.5)	21.5 (18.0, 24.5)	0.2059	25.0 (15.8, 38.5)	26.0 (17.0, 43.5)	0.7613	0.5872
ALT (U/L)	27.5 (13.0, 44.8)	22.0(13.0, 35.2)	0.0828	22.0 (14.0, 34.3)	23.0 (14.0, 43.0)	0.5888	0.1726
GGT (U/L)	28.0 (21.8, 55.8)	26 (18.0, 39.0 )	0.0010	24.0 (18.5, 39.5)	22.0 (19.0, 41.0)	0.7268	0.0133
eGFR (ml/min/1.73m <sup>2</sup> )	77.4±22.0	73.3±22.9	0.0048	71.4±25.7	66.4±24.5	0.7608	0.3320
Uric acid (mg/dl)	5.4±1.3	4.9±1.4	0.0003	5.9±1.4	5.8±1.6	0.6432	0.0589
Hematocrit (%)	42.7±4.1	45.8±4.5	0.0001	40.0±4.8	40.1±4.5	0.2707	0.0014
Platelets(×10 <sup>9</sup> /mL)	24.3±6.0	24.4±5.6	0.8941	24.1±7.2	24.1±7.2	0.6386	0.5028
MPV (fl)	10.1±0.6	10.1±0.6	0.9064	10.6±1.4	10.8±1.6	0.5046	0.6192
PAI-1 (ng/ml)	32.5 (22.0, 53.0)	26.0 (22.0, 33.0)	0.0014	36.5 (18.8, 55.0)	36.0 (20.5, 64.0)	0.0059	<0.0001
PAP (μg/ml)	0.70 (0.50, 0.80)	0.70 (0.50, 1.00)	0.3672	0.70 (0.58, 0.95)	0.80 (0.48, 1.15)	0.2825	0.9110
TAT (ng/ml)	2.0 (1.1, 3.3)	1.6 (1.3, 2.4)	0.3039	2.9 (1.7, 7.6)	4.2 (2.1, 6.8)	0.3824	0.2301
HMW adiponectin (μg/ml)	1.66 (0.82, 2.54)	1.76 (0.97, 3.49)	0.0304	2.75 (1.52, 7.32)	3.29 (1.81, 5.01)	0.7467	0.0752
Leptin (ng/ml)	12.8 (6.5, 19.4)	12.2 (6.4, 19.7)	0.4016	12.4 (7.5, 24.1)	10.7 (6.7, 24.0)	0.2522	0.4330

Data are mean ± SD or the median and inter-quartile ranges.

BMI, body mass index; VFA, visceral adipose area; SBP, systolic blood pressure; DBP, diastolic blood pressure; FPG, fasting plasma glucose; LDL-C, low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol; RLP-C, remnant like lipoprotein cholesterol; AST, aspartate aminotransferase;

ALT, alanine transaminase; GGT,  $\gamma$ -glutamyltranspeptidase; eGFR, estimated glomerular filtration; PAI-1, plasminogen activator inhibitor-1; PAP, plasmin- $\alpha$ 2-antiplasmin complex ; TAT, thrombin-antithrombin III complex; HMW, high-molecular weight;